Maresin 1 Repletion Improves Muscle Regeneration After Volumetric Muscle Loss
Abstract The acute traumatic or surgical loss of skeletal muscle, known as volumetric muscle loss (VML), is a devastating type of injury that results in exacerbated and persistent inflammation followed by fibrosis. The mechanisms that mediate the magnitude and duration of the inflammatory response and ensuing fibrosis after VML remain understudied and as such, the development of regenerative therapies has been limited. To address this need, we profiled how lipid mediators, which are potent regulators of the immune response after injury, varied with VML injuries that heal or result in fibrosis. We observed that non-healing VML injuries displayed increased pro-inflammatory eicosanoids and a lack of pro-resolving lipid mediators. Treatment of VML with a pro-resolving lipid mediator synthesized from docosahexaenoic acid, called Maresin 1, ameliorated fibrosis through reduction of neutrophils and macrophages and improved myogenesis, leading to enhanced recovery of muscle strength. These results expand our knowledge of the dysregulated immune response that develops after VML and identify a novel immuno-regenerative therapeutic modality in Maresin 1..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Castor-Macias, Jesus A. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.11.19.517113 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI037933744 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI037933744 | ||
| 003 | DE-627 | ||
| 005 | 20240424104652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.11.19.517113 |2 doi | |
| 035 | |a (DE-627)XBI037933744 | ||
| 035 | |a (biorXiv)10.1101/2022.11.19.517113 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Castor-Macias, Jesus A. |e verfasserin |0 (orcid)0000-0002-2501-1035 |4 aut | |
| 245 | 1 | 0 | |a Maresin 1 Repletion Improves Muscle Regeneration After Volumetric Muscle Loss |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The acute traumatic or surgical loss of skeletal muscle, known as volumetric muscle loss (VML), is a devastating type of injury that results in exacerbated and persistent inflammation followed by fibrosis. The mechanisms that mediate the magnitude and duration of the inflammatory response and ensuing fibrosis after VML remain understudied and as such, the development of regenerative therapies has been limited. To address this need, we profiled how lipid mediators, which are potent regulators of the immune response after injury, varied with VML injuries that heal or result in fibrosis. We observed that non-healing VML injuries displayed increased pro-inflammatory eicosanoids and a lack of pro-resolving lipid mediators. Treatment of VML with a pro-resolving lipid mediator synthesized from docosahexaenoic acid, called Maresin 1, ameliorated fibrosis through reduction of neutrophils and macrophages and improved myogenesis, leading to enhanced recovery of muscle strength. These results expand our knowledge of the dysregulated immune response that develops after VML and identify a novel immuno-regenerative therapeutic modality in Maresin 1. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Larouche, Jacqueline A. |e verfasserin |0 (orcid)0000-0001-9380-3547 |4 aut | |
| 700 | 1 | |a Wallace, Emily C. |e verfasserin |4 aut | |
| 700 | 1 | |a Spence, Bonnie D. |e verfasserin |4 aut | |
| 700 | 1 | |a Eames, Alec |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Benjamin A. |e verfasserin |0 (orcid)0000-0001-7412-6261 |4 aut | |
| 700 | 1 | |a Davis, Carol |e verfasserin |0 (orcid)0000-0003-3082-8995 |4 aut | |
| 700 | 1 | |a Brooks, Susan V. |e verfasserin |0 (orcid)0000-0003-1954-967X |4 aut | |
| 700 | 1 | |a Maddipati, Krishna Rao |e verfasserin |0 (orcid)0000-0003-1445-791X |4 aut | |
| 700 | 1 | |a Markworth, James F. |e verfasserin |0 (orcid)0000-0002-5348-1464 |4 aut | |
| 700 | 1 | |a Aguilar, Carlos A. |e verfasserin |0 (orcid)0000-0003-3830-0634 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.7554/elife.86437 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.11.19.517113 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||